CLINICAL ASSISTANT PROFESSOR, DEPARTMENT OF OPHTHALMOLOGY KECK SCHOOL OF MEDICINE, USC

MODERATOR: Sheldon Kishineff, M.D.; Pediatric Liaison, Medical Education Committee

FACULTY DISCLOSURE: According to CMA guidelines for faculty and planner disclosure of commercial support, we are required to announce the following:
Dr. Fierson states he has nothing to disclose.
Dr. Kishineff states he has nothing to disclose.

OBJECTIVES At the end of the presentation, attendees will be able to:

• • define learning disabilities and dyslexia and distinguish them from other forms of developmental disability.
• • discuss the pathophysiology of learning disabilities and dyslexia in modern neurological terms, and describe how they should and should not be treated
• • appropriately advise parents who are asking for advice on the subject
• • identify cultural/linguistic factors that impact the epidemiology, incidence, diagnosis, treatment, clinical course, and/or long-term outcomes of learning disabilities and dyslexia.

PROFESSOR OF MEDICINE; CHIEF, DIVISION OF RHEUMATOLOGY; DEPT. OF MEDICINE DAVID GEFFEN SCHOOL OF MEDICINE, UCLA

MODERATOR: PENG FAN, M.D.; MEMBER, MEDICAL EDUCATION COMMITTEE, PSJMC

FACULTY DISCLOSURE:According to CMA guidelines for faculty disclosure of commercial support, we are required to announce the following:
Dr. Hahn states she is a consultant for Biogen IDEC, Bristol Myers Squibb and Idera Pharmaceuticals, is a grant recipient from Aspreva, and is on the Data Safety Monitoring Board for Bristol Myers Squibb.

OBJECTIVES At the end of the presentation, attendees will be able to:

• discuss current thoughts regarding pathogenesis of SLE
• recognize the signs and symptoms of SLE, conduct an appropriate work-up, and make the diagnosis
• incorporate current therapeutic approaches to SLE
• identify cultural/linguistic factors that impact the epidemiology, incidence, diagnosis, treatment, clinical course, and/or long-term outcomes of SLE